Quintessence study on the scrutinize treatment of rheumatoid arthritis by monoclonal antibodies manoeuvres

SS Pravin*, M Mohana Krishna, R Kavitha

SRM College of Pharmacy, SRM Institute of Scienceand Technology, Kattankulathur, Chengalpattu, Tamil Nadu, India

Refer this article

SS Pravin, M Mohana Krishna, R Kavitha, 2025. Quintessence study on the scrutinize treatment of rheumatoid arthritis by monoclonal antibodies manoeuvres. Journal of medical pharmaceutical and allied sciences, V14 - I 1, Pages - 6982 – 6987. Doi: https://doi.org/10.55522/jmpas.V14I1.6786.

ABSTRACT

In a standard pathology lab or when it aids in clinical diagnosis and patient care, monoclonal antibodies act effectively. In order to provide a better understanding and provide a therapeutic strategy for rheumatoid arthritis, the synthesis and applications of monoclonal antibodies are discussed in this article. A monoclonal antibody therapy targets foreign substances that are damaging to the body and imitates the immune system's normal reaction. In both contemporary and future medical practice, monoclonal antibodies represent a potent kind of therapy. There are different types of monoclonal antibodies which are Murine, secondly the Chimeric, thirdly Humanized, Human. A monoclonal antibody that targets the pathogenic cytokine and cellular components present in the RA synovium is the most common type of biologic created to date. All of the immune cells are clones of a single parent cell, known as immune cells, create monoclonal antibodies (mAbs), which are monospecific antibodies. Anti-CD4, anti-CD7, and CAMPATH-1H were the goals of the initial research utilizing mAbs in RA, with various degrees of effectiveness and serious safety issues. However, the US FDA has approved the use of polyspecific mAbs that are directed against a variety of distinct target molecules for the medical intervention of RA. These include TNF-α, B cells that are CD20-positive, IL-1, and IL-6. Etanercept and Abatacept are two more biological medicines that have been authorized for the treatment of RA; they are fusion proteins rather than monoclonal antibodies. Remarkable advancements were achieved that made it possible to manufacture antibodies with altered molecular characteristics, such valence., terms of size, precision, and propensity. The half-life of serum and mechanism of effect can also be further tuned thanks to advances in antibody engineering technology. In order to get meaningful results from systemic therapy and prevent adverse side effects, optimal distribution to the intended tissue must still be dealt with.

Keywords:

Monoclonal antibody, Mouse monoclonal antibodies, Synovim, Rheumatoid arthritis, Hybridoma cells.

Full Text Article